Profound Medical (TSE:PRN) has released an update.
Profound Medical Corp. reported a 39% increase in Q2 2024 revenue, reaching $2.23 million, driven by sales of TULSA-PRO systems and consumables, amidst ongoing efforts to expand the installed base and prepare for future CMS reimbursement changes. The company is also advancing with its CAPTAIN trial and FDA-cleared TULSA-AI module, indicating a strong commercial trajectory.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
